uniQure: A High-Risk, High-Reward Investment Opportunity
uniQure (NASDAQ:QURE) is on track to read out data from its pivotal trial of AMT-061 for patients with hemophilia B. Given the gene therapy appears safe, the company can complete the pivotal trial and eventually file for a regulatory approval. The closing of the deal with CSL Behring may provide significant cash flow to fund the pipeline. uniQure remains a high-risk, high-reward investment due to the Huntington’s disease program.
AMT-061 appears to have a favorable safety profile